Pioneering Disease Solutions
Corporate Profile
American Gene Technologies (AGT) is a private biotechnology company supported by accredited investors. The company develops genetic medicines that meet unmet medical needs in inherited or acquired diseases through the application of viral vector technology. AGT is pioneering disease solutions to achieve permanent cures for human diseases.
Primary IR Contact: Norman Rogers.
ABOUT AMERICAN GENE
Overview
AGT, has a broad viral vector delivery platform evolved over ten years of advanced development. AGT has an extensive and growing patent portfolio surrounding its platform of innovations that accelerate the development of a wide variety of drug candidates. From this foundation, AGT pursues exciting clinical "cures" in large and orphan indications and complex diseases. AGT's proprietary platform technologies provide reusable
components that allow AGT and its internationally recognized collaborators to create new therapies in a fraction of the time of traditional drug development and other drug companies. AGT began clinical trials this year for an HIV cure. AGT has built a rich product pipeline of genetic therapies for patients suffering from infectious disease, monogenic disorders, and cancer, using its viral vector platform and patented methods.
Lead Programs
Pipeline
Financial Momentum
Third-Party Reports
AGT hosted an analyst day to provide insight into the status of HIV therapy, including cure research, which provides a context for understanding the unique features and advantages of the company's AGT103-T cell and gene therapy for HIV. The even was hosted shortly before the IND was submitted.
AGT is followed by the analyst listed above. Please note that any opinions, estimates or forecasts regarding AGT’s performance made by the analyst are his alone and do not represent opinions, forecasts or predictions of AGT or its management. AGT does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.
U.S. Patent & Trademark
Patents
AGT's patent portfolio protects its technology platform and methods. In addition to the granted patents below, AGT has several patents pending and over 20 patent families represented by filings with the USPTO and international patent offices. Also, AGT has been granted FDA Orphan Drug Designation for its treatment of Phenylketonuria (PKU).
AGT is a private company supported by accredited investors.
Investor Relations Primary Contact, Norman Rogers
Lead Candidate
HIV Program Milestones
August 2020
FDA approves AGT’s Investigational New Drug (IND) application, greenlighting Phase 1 clinical trials for AGT103-T. The Phase 1 will be conducted in selected trial sites in the Baltimore/D.C. metropolitan area.
November 2020
The first trial participant was enrolled in the study and underwent leukapheresis, a procedure for obtaining concentrated white blood cells. Those cells will be used to manufacture the AGT103-T cell product.
In the New Year
AGT103-T to be Infused
Manufacturing AGT103-T from the participant's blood takes 11 days, and from there, FDA-mandated safety testing begins. Should the blood product meet the release criteria as expected, the trial participant is due to be infused early in 2021.
How AGT103-T HIV Therapy Is Different?
AGT is a private company supported by accredited investors.
Investor Relations Primary Contact, Norman Rogers
Latest News
Press Releases
Download
Science Deck
In over a decade of development, AGT has accrued a huge bank of tools and reusable components that can be mixed and matched to solve fundamental hurdles across a broad range of disease.
"The team here at AGT is really exceptional. The quality of the work and the innovation that goes on here is one of the things that has attracted me because I can see how some of these technologies could be applied to breast cancer."
– Robert Clarke, PhD, DSc
Georgetown University Medical School
"AGT has become one of these companies that resonates on my personal level of looking for new technologies, new advances, and really as they really try to push the line on therapies for terrible diseases like HIV."
– Ely Benaim, MD
Chief Medical Officer, Novocure
We're happy to help
Contact Us
Primary IR Contact
Norman Seth Rogers
Business Development, Investor Relations
Sign-up For Our Newsletter
We send out quarterly newsletters that keep you up-to-date on all our projects, progress, and events.
